KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Thermo Fisher Scientific (TMO) over the last 16 years, with Sep 2025 value amounting to $3.2 billion.

  • Thermo Fisher Scientific's Other Accumulated Expenses fell 5.42% to $3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year decrease of 5.42%. This contributed to the annual value of $3.2 billion for FY2024, which is 1.45% down from last year.
  • As of Q3 2025, Thermo Fisher Scientific's Other Accumulated Expenses stood at $3.2 billion, which was up 0.28% from $3.2 billion recorded in Q2 2025.
  • In the past 5 years, Thermo Fisher Scientific's Other Accumulated Expenses registered a high of $3.4 billion during Q3 2024, and its lowest value of $1.9 billion during Q3 2021.
  • Its 3-year average for Other Accumulated Expenses is $3.1 billion, with a median of $3.0 billion in 2025.
  • In the last 5 years, Thermo Fisher Scientific's Other Accumulated Expenses spiked by 58.89% in 2022 and then decreased by 11.17% in 2023.
  • Thermo Fisher Scientific's Other Accumulated Expenses (Quarterly) stood at $3.0 billion in 2021, then climbed by 13.69% to $3.4 billion in 2022, then dropped by 3.22% to $3.2 billion in 2023, then fell by 1.45% to $3.2 billion in 2024, then declined by 5.42% to $3.2 billion in 2025.
  • Its Other Accumulated Expenses was $3.2 billion in Q3 2025, compared to $3.2 billion in Q2 2025 and $3.0 billion in Q1 2025.